Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Montevialeon Nov 15, 2017 5:15pm

164 Views

Post# 26971704

Aphria Sold their Position in Kalytera

I mentioned a while back that Aphria most likely liquidated their shares in Kalytera, but I thought it might be worth repeating since a lot of specualtion on here today about Aphria's position in the company. If you look at current Investor Deck for Aphria you will notice that Kalytera has been removed from investment list of science plays. If they havent sold their shares then why would they omit the company?

Wiht or without Aphria it was a good day.

M

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!